21253-62-3

Upstream product

• 108-85-0 1-bromocyclohexane 
• 6994-25-8 3-amino-4-pyrazolecarboxylic acid ethyl ester 
• 42466-67-1 ethyl (ethoxymethylene)cyanoacetate 
• 24214-73-1 cyclohexylhydrazine hydrochloride 
• 94-05-3 ethyl (ethoxymethylene)cyanoacetate 
• 6498-34-6 cyclohexylhydrazine 
• 94-05-3 2-cyano-3-ethoxyacrylic acid ethyl ester 

Downstream Products

• 950859-24-2 5-chloro-1-cyclohexyl-1H-pyrazole-4-carboxylic acid ethyl ester 
• 3528-50-5 1-cyclohexyl-1H-pyrazol-5-amine 
• 1023301-92-9 (5-amino-1-cyclohexylpyrazol-4-yl)-N-(4-methoxyphenyl) carboxamide 

Relevant academic research and scientific papers

The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition

In this study, a series of sulfonamide compounds was designed and synthesized through the systematic optimization of the antibacterial agent sulfaphenazole for the treatment of Mycobacterium tuberculosis (M. tuberculosis). Preliminary results indicate that the 4-aminobenzenesulfonamide moiety plays a key role in maintaining antimycobacterial activity. Compounds 10c, 10d, 10f and 10i through the optimization on phenyl ring at the R2 site on the pyrazole displayed promising antimycobacterial activity paired with low cytotoxicity. In particular, compound 10d displayed good activity (MIC = 5.69 μg/mL) with low inhibition of CYP 2C9 (IC50 > 10 μM), consequently low potential risk of drug-drug interaction. These promising results provide new insight into the combination regimen using sulfonamide as one component for the treatment of M. tuberculosis.

A Michael Equilibration Model to Control Site Selectivity in the Condensation toward Aminopyrazoles

A Michael equilibration model is presented to provide for site-selective pyrazole condensations between alkoxyacrylonitriles and hydrazines. Both pyrazole isomers were accessed with high selectivity by employment of kinetically or thermodynamically controlled conditions. Substrate scope and identification of Michael intermediates, as well as competitive pathways, support the presented mechanistic proposal. Sandmeyer derivatization provided site-selective access to fully substituted pyrazoles.

Substituted pyrazolopyrimidines

The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I): wherein R1, R2, R3, R4, R5, X, W, and ring A are as defined herein; pharmaceutical compositions of substituted heterobicyclic pyrimidines of Formula (I); and their use in the treatment of chronic neurodegenerative diseases, neurotraumatic diseases, depression and/or diabetes. More particularly, the present invention relates to substituted pyrazolopyrimidines of Formula (I).

AZOLOPYRIMIDINES AS INHIBITORS OF CANNABINOID 1 ACTIVITY

The invention provides compounds of formula (Ia), (Ic), (Ig) and (Ik), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).

Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).